
oct pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
nm price-to-earnings oper ep
risk assess reflect view
depend expand number approv use
soliri support premium valuat mani new
explor indic earli middl stage
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
look sale rise
sale key drug soliri increas
see continu momentum strensiq lead
sale year-over-year
growth slower strategi kanuma
result sale growth
diseas therapi pipelin
wilson diseas area
new treatment year expect
leverag expertis manag rare diseas
treatment success launch
phase switch data
show patient paroxysm
nocturn hemoglobinuria pnh effect
safe switch treatment soliri everi
week treatment everi week
safeti profil consist soliri
total data favor
soliri file approv
treat pnh expect
treatment launch earli
think trade
ep estim
under-valued still urg caution
concentr primari drug soliri
revenu think
sever catalyst signific upsid
potenti given expertis manag
develop market rare diseas
treatment high expect
expand indic soliri late-stag
pipelin product
exampl grow expertis
launch soliri gener myasthenia
gravi gmg patient full quarter
launch patient
increas addit pnh
work get approv
patient ahu import
futur drug insul
soliri biosimilar competit
risk recommend target price
includ weak sale growth soliri pipelin
failur competit threat unfavor
target price base
peer ep
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
independ chairman
board
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
first market product soliri eculizumab first therapi approv treatment patient
paroxysm nocturn hemoglobinuria pnh soliri design inhibit specif aspect
complement compon immun system therebi treat inflamm associ chronic
hematolog neurolog disord transplant reject autoimmun disord
soliri human monoclon antibodi complement inhibitor block cleavag compon
complement cascad prevent final stage complement activ soliri
develop treatment pnh rare blood disord caus anemia fatigu dark-color
urin hemoglobinuria pnh portion patient red blood cell miss complement inhibitor
caus abnorm fragil destroy normal complement activ
estim pnh patient european union japan said expect
pnh popul come rest world prior soliri
soliri also approv second indic rare kidney diseas atyp hemolyt urem syndrom
ahu often lead end-stag kidney diseas failur carri high mortal rate
septemb fda approv soliri use european union regul approv drug
novemb although ahu seen modest launch trajectori state
expect opportun rival pnh
strensiq asfotas alfa target enzym replac therapi approv therapi patient
hypophosphatasia design directli address underli caus aim restor
genet defect metabol process therebi prevent revers sever potenti
life-threaten complic patient food drug administr fda
approv strensiq patient perinatal- infantile- juvenile-onset european
commiss ec grant market author strensiq treatment patient
pediatric-onset ministri labour welfar mhlw approv strensiq
treatment patient compani sponsor multi-national registri gather inform
regard natur histori patient long-term outcom strensiq
kanuma sebelipas alfa recombin form human lal enzym enzyme-replac
therapi approv treatment patient lal-d fda approv kanuma
treatment patient lal-d ec grant market author kanuma long-term
enzym replac therapi patient age lal-d mhlw approv kanuma
treatment patient age japan lal-d compani sponsor multi-national
registri gather inform regard natur histori patient lal-d long-term
outcom kanuma treatment
pipelin long-act inhibitor work inhibit protein termin
complement cascad earli studi demonstr sustain reduct free level
alexion complet enrol four on-going clinic studi patient pnh
includ open-label phase i/ii dose-escal studi evalu safeti toler efficaci
pharmaco-kinet pk pharmaco-dynam pd administ intraven iv
infus phase ii open-label studi evalu efficaci safeti toler immunogen pk
pd administ iv infus investig multipl dose interv four twelv
week phase open-label random active-control multicent studi evalu safeti
efficaci versu eculizumab administ iv infus adult patient pnh
never receiv treatment complement inhibitor phase open-label random
active-control multicent studi evalu safeti efficaci versu eculizumab
administ iv infus adult patient pnh treat eculizumab least
past month
impact major develop june acquir synageva biopharma geva nr
billion consist cash share geva share geva
focus rare diseas geva kanuma treatment lysosom acid lipas defici orphan
drug statu us eu
financi trend sale risen billion billion repres
three-year compound annual growth rate compound-annual-growth-rate gross margin rang
 cost rose million sale million
sale adjust ep risen repres three-year
compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook biotechnolog
sub-industri tradit defens
next month posit reflect
favor prospect commerci
new therapi biotechnolog compani
trade signific discount
market think remedi
robust pipelin drug brought market
fda approv new drug
sinc record
approv think mani
newly-approv drug drug late-stag
clinic trial consider commerci
prospect repres major advanc
therapi diseas cystic fibrosi
hepat multipl sclerosi cancer
exampl fda approv first
gene-therapi drug genet alter
patient immun cell first-ev
think growth biotechnolog stock
slightli limit high drug price
us heighten scrutini
us polit apparatu last
year despit talk lower drug
price seen particularli sever
measur taken us govern lower
drug price far center medicar
 medicaid introduc option step
therapi part drug attempt lower
treatment cost current administr
also propos elimin rebat
drug manufactur pay pharmaci benefit
manag neither measur
like significantli impact drug
manufactur think mid-term
elect earli novemb could provid
insight futur regulatori propos
anoth sourc price pressur drug
manufactur pharmaci benefit manag
pbm health insur exert
influenc drug prescript
price pressur like increas
health care industri continu
consolid merger note includ
cvs-aet ci-esrx combin
expect wider adopt biomark
research genetic-target clinic
studi bolster long-term pipelin
product merger acquisit
 climat near futur appear
favor larg pharmaceut
biotechnolog firm look off-set
lost revenu expir patent
matur product promis late-stag
compani low debt level modest
valuat reason favor
biolog price competit
innov act bpcia grant
exclus period brand biolog
aggress use patent law
delay commerci biosimilar
effect extend period
result expect biosimilar advanc
slowli next sever year howev
biosimilar approv
introduc expect growth
biosimilar acceler
year date septemb
 biotech index rose vs
rise
biotech index rose vs rise
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
significantli follow posit top-lin phase switch clinic trial data
show patient paroxysm nocturn
hemoglobinuria pnh effect safe switch treatment soliri
everi two week treatment everi eight week studi show
non-inferior soliri primari endpoint four secondari endpoint
safeti profil consist soliri believ total
data favor soliri plan file regulatori submiss
 europ japan howev
uncertain mani patient stabl soliri make switch
inc lower target
slightli above-p ep estim
set ep ep vs ahead
estim sale rose soliri sale strensiq
kanuma much lower base guid sale
soliri sale ep expect data
phase trial treat paroxysm nocturn
hemoglobinuria pnh debilit potenti life-threaten rare
blood disord /jeffrey loo cfa
keep target
peer forward ep ep vs
ahead view rais ep estim
sale rose soliri sale
strensiq kanuma rose much smaller base see steadi
growth soliri sale fda emea approv addit
indic also look improv strensiq sale fund deal
england becom effect novemb new agreement franc becom
effect /jeffrey loo cfa
analyst research note compani news
inc lift target
above-p ep estim
ep vs higher estim rais
ep lower ep sale
increas million soliri sale grew million
volum increas end septemb gener myasthenia
gravi gmg patient soliri therapi increas
number patient end june launch soliri gmg
turn success soliri launch expect
launch drive continu revenu growth think guidanc
increas quarter larg success gmg launch
also announc collabor discov
develop rnai therapi complement-medi diseas ad four rnai
candid pre-clin develop /kevin huang cfa
et cfra reiter buy opinion share alexion
trade pre-market today
posit top-line result phase prevent studi soliri patient
auto antibody-posit neuromyel optica
spectrum disord nmosd nmosd rare devast central nervou
system disord character relaps result increment
disabl symptom prevent studi met primari endpoint
demonstr treatment soliri reduc risk nmosd relaps
compar placebo current approv therapi
diseas expect detail result phase studi present
buy hold lift target
above-p ep estim
encourag success expans key drug soliri
revenu new indic rais ep
ep think soliri launch treatment
myasthenia gravi approv octob perform better expect
reflect expertis manag develop market
rare diseas treatment see upsid pipelin particularli
expect launch upon approv
 regulatori bodi also see posit potenti june
acquisit wilson therapeut ad anoth late-stag rare diseas
therapi much upsid potenti caution
compani risk still highli concentr primari drug soliri
gener revenu /kevin huang cfa
rais target price
slightli peer forward ep estim
see grow faster peer posit view
rare diseas pipelin ep vs ahead
estim rais ep estim ep
estim sale rose volum rose driven
robust launch soliri treat gener myasthenia gravi gmg overal
soliri sale rose volum growth strensiq sale rose
kanuma sale rose encourag pipelin progress
file approv treat paroxysm nocturn hemoglobinuria
pnh europ expect file japan phase
trial treat atyp hemolyt urem syndrom ahu
on-going expect data earli /jeffrey loo cfa
keep target price
slightli peer ep estim
ep vs ahead estim sale rose
soliri sale strensiq kanuma share
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
